aripiprazole / Generic mfg. - LARVOL DELTA

Albumin Quality in Oxidative and Ischemic Stress: Implications for Drug Binding and Clinical Pharmacokinetics. (PubMed, Biol Pharm Bull) - "Experimental and clinical evidence suggests that oxidative modification of HSA can either diminish or enhance drug binding, as observed with aripiprazole and methotrexate, respectively, resulting in significant interindividual variability in pharmacodynamic responses. Future work should clarify how modified HSA affects clearance pathways and whether exogenous albumin is similarly oxidized in vivo. Understanding these qualitative alterations may improve pharmacotherapy in critically ill and chronically inflamed patients."

Journal • PK/PD data • Review • Cardiovascular • Diabetes • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Septic Shock

Unmasking Hidden Malignant Cutaneous Lesions Following Treatment of Extensive Pityriasis Rubra Pilaris: A Case Report (EADV 2026) - "His medical history included schizophrenia treated with clozapine and aripiprazole...Treatment with risankizumab resulted in marked clinical improvement, with the resolution of erythema, scaling, and keratoderma...Disease control may reveal previously undetectable lesions, emphasizing the importance of careful skin examination during and after treatment. Clinicians should be aware of this phenomenon to avoid delayed diagnosis of cutaneous malignancies."

Case report • Clinical • Basal Cell Carcinoma • CNS Disorders • Dermatopathology • Non-melanoma Skin Cancer • Schizophrenia • Skin Cancer

DRESS Syndrome: A Tertiary Centre Case Series with Comparative Analysis of Clinical Presentation, Histopathology and Laboratory Findings (EADV 2026) - "Culprit drugs included aromatic anticonvulsants (carbamazepine n=2, lamotrigine n=1), antibiotics (n=4), sulfasalazine (n=1), naproxen (n=1), and antimycobacterials (n=1)...The most severe complication was steroid-induced psychosis in a 74-year-old patient requiring MHA Section 2 detention, aripiprazole, and transfer to inpatient psychiatric care...This series highlights a novel putative culprit (atogepant), the risk of significant iatrogenic morbidity from corticosteroids (including severe neuropsychiatric complications) and the importance of long-term autoimmune surveillance post-resolution. These findings reinforce the need for early recognition, standardised workup including viral reactivation studies and skin biopsy, and an individualised, multidisciplinary approach to management."

Clinical • Chronic Spontaneous Urticaria • CNS Disorders • Endocrine Disorders • Eosinophilia • Grave’s Disease • Immunology • Neuralgia • Renal Disease • Urticaria

Obsessive-Compulsive Disorder in Adulthood: Etiology, Diagnosis, and Treatment. (PubMed, Dtsch Arztebl Int) - "Effective evidence-based treatments for OCD are already available, and promising new approaches are being studied. A major challenge remains in making these disorder-specific treatments available to patients with OCD."

Journal • Review • CNS Disorders • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Psychiatry • Psychosomatic Disorders • Tourette Syndrome

Aripiprazole attenuates hippocampal theta oscillations during sleep in mice (Neuroscience 2026) - "In addition, the aripiprazole-treated group demonstrated significant attenuation in the power of the hippocampal theta band during both REM and NonREM sleep.Our results suggest that neural plasticity and cognitive function are impaired even in healthy mice by aripiprazole-attenuated theta oscillations, as hippocampal theta oscillations are involved in memory processing. Our study presents a novel aspect of the working mechanisms of antipsychotic drugs and serves as basic evidence for managing side effects and considering their impacts on cognitive function in clinical settings."

Preclinical • Bipolar Disorder • CNS Disorders • Mood Disorders • Schizophrenia • DRD2

Antipsychotic-Associated Sexual Dysfunction in Schizophrenia: A Network Meta-Analysis With Bayesian Receptor Affinity Correlation Analysis (Neuroscience 2026) - "For any sexual dysfunction, aripiprazole (risk ratio, 0.44; 95% CI, 0.31-0.63), ziprasidone (0.64; 0.52-0.80), and quetiapine (0.71; 0.61-0.84) were associated with lower risks than risperidone, whereas sertindole showed higher risk (2.89; 1.74-4.82). Antipsychotics differ meaningfully in sexual dysfunction risk, with exploratory receptor analyses suggesting domain-specific pharmacological patterns. These findings support routine assessment of sexual function and may inform individualized antipsychotic selection."

Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Drug-Specific Treatment Persistence in Pediatric Attention-Deficit/Hyperactivity Disorder: A Nationwide Japanese Cohort Study (Neuroscience 2026) - "We identified 29,257 children aged 6-17 years (74.5% male; mean age 10.3±3.3 years) initiating osmotic controlled-release oral delivery system methylphenidate (OROS-MPH, n=9,846), atomoxetine (ATX, n=8,135), or guanfacine extended-release (GXR, n=11,276), followed up to 730 days...Persistence was compared using Kaplan-Meier and log-rank tests; drug-group-specific Cox models were fitted within each cohort, adjusting for age, sex, prescribing specialty, and concomitant melatonin, risperidone, and aripiprazole...Determinants of treatment persistence in ADHD pharmacotherapy are not uniform across agents, supporting drug-specific persistence strategies. This study was approved by the Research Ethics Review Committee of Meiji Pharmaceutical University (registration number: 202408)."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Hydrogel-Based Depot Systems in Psychiatric Pharmacotherapy: A Narrative Review Rethinking Long-Acting Drug Delivery. (PubMed, Gels) - "Current research has primarily focused on antipsychotic delivery, where hydrogel formulations of risperidone, paliperidone, aripiprazole, olanzapine, quetiapine and the investigational peptide PAOPA show possible sustained drug release and prolonged therapeutic activity in preclinical models...Collectively, current evidence supports the technological potential of hydrogel-based systems to provide tunable drug loading, depot formation, and sustained release. However, their development as clinically meaningful next-generation LAI therapies will require long-term in vivo evaluation, robust pharmacokinetic-pharmacodynamic characterization, injection-site safety assessment, reproducible and scalable manufacturing, and well-designed clinical trials."

Journal • Review • CNS Disorders • Mental Retardation • Psychiatry

Multi criteria evaluation of schizophrenia drugs: DFT, ADMET, and molecular docking investigations. (PubMed, Comput Biol Chem) - "Global reactivity descriptors indicated a higher oxidative stability in aripiprazole, opposite to the marked reactivity sensitivity of haloperidol...Structural divergence was observed in Olanzapine and Haloperidol...Risperidone showed the highest affinity (-10.0 kcal/mol) due to strong electrostatic interactions with the primary anchoring residue Asp474 and hydrophobic stabilisation through Tyr142, Trp322 and Pro383...The MEP maps confirmed that the binding affinity to GlyT1 is the large negative potential localisation around the hydrogen-bond accepting heteroatoms, as well as the large electrochemically neutral hydrophobic regions. These insights provide a crucial integrated framework for optimising the next generation antipsychotic drug design."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder (clinicaltrials.gov) - P=N/A | N=155 | Completed | Sponsor: Dong-Wook Kim

New trial • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

REORDER: A Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia. (clinicaltrials.gov) - P2 | N=121 | Completed | Sponsor: EMS

New P2 trial • CNS Disorders • Psychiatry • Schizophrenia

Longitudinal cardiometabolic trajectories in children and adolescents in therapy with second-generation antipsychotics: a real-world multicenter study. (PubMed, Front Psychiatry) - "While demonstrating an acceptable tolerability profile, risperidone and aripiprazole were associated with different cardiometabolic and endocrine variations over a 24-month period in this real-world pediatric cohort. These findings should be interpreted within the context of the study's observational nature and of potential confounding factors (e.g., unmeasured dietary, physical activity, and pubertal factors), highlighting the clinical necessity of longitudinal monitoring in children and adolescent patients."

Clinical • Journal • Real-world evidence • Autism Spectrum Disorder • Cardiovascular • CNS Disorders • Genetic Disorders • Pediatrics • Psychiatry

Comparative efficacy of antipsychotics for reducing aggression in schizophrenia: systematic review and network meta-analysis. (PubMed, Br J Psychiatry) - "Antipsychotics reduced hostility and aggressive behaviour in predominantly short- to medium-term studies. Clozapine, paliperidone and olanzapine appeared most effective, although low-certainty evidence limits conclusions about differences between antipsychotics. Further trials with aggressive behaviour as the primary outcome and longer follow-up are needed."

Journal • Retrospective data • Review • CNS Disorders • Psychiatry • Schizophrenia

Real-world adherence, healthcare resource utilization, and costs following a transition to aripiprazole once every 2 months among patients diagnosed with bipolar I disorder in the United States. (PubMed, Front Psychiatry) - "Aripiprazole monohydrate is available as LAI formulations administered once-monthly [aripiprazole once-monthly (AOM)] or once every 2 months (aripiprazole 2-month ready-to-use [Ari 2MRTU]). Inpatient visits (all-cause, BP-I-related), and all-cause LOS decreased, along with all-cause ED and total medical costs. Transitioning to Ari 2MRTU was associated with improved treatment adherence and reduced selected HCRU measures and total medical costs, supporting its value as a treatment option for BP-I."

HEOR • Journal • Real-world evidence • Bipolar Disorder • CNS Disorders • Psychiatry

Regulating the Hyperdopaminergic Substrate in Restless Legs Syndrome With Augmentation: An Open-label Study on the Safety and Efficacy of Aripiprazole. (PubMed, Clin Neuropharmacol) - "Low-dose morning aripiprazole was effective and well tolerated in patients with severe RLS and augmentation, enabling complete DA withdrawal and substantial improvement in RLS symptoms and sleep. These findings suggest that dopaminergic stabilizers could be a promising therapeutic option for RLS with augmentation. Controlled trials are warranted to confirm these results."

Journal • CNS Disorders • Fatigue • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study. (PubMed, Front Pharmacol) - "Risperidone, paliperidone and sulpiride showed an increasing trend with elevated PRL levels, whereas quetiapine and aripiprazole were more frequently prescribed in the low-risk HPRL group. Based on homogeneous clinical real-world data, this study comprehensively evaluated multiple antipsychotic medications simultaneously. It provides empirical clinical evidence for individualized medication strategies in patients with comorbid HPRL and EPS, and offers real-world evidence for the clinical early risk recognition, and long-term medication decision-making among patients with multiple adverse reactions concurrently."

Journal • Real-world evidence • Retrospective data • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia • PRL

High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden-A Register-Based Study. (PubMed, Pharmacoepidemiol Drug Saf) - "The overall risk of metabolic side effects is considerable, with higher relative risks in girls, especially younger girls. These findings highlight the need for carefully considered treatment and attentive monitoring when initiating antipsychotics in children."

Adverse events • Journal • CNS Disorders • Genetic Disorders • Obesity • Pediatrics

Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: University of Alabama at Birmingham | Trial completion date: Dec 2026 ➔ Oct 2027 | Trial primary completion date: Dec 2026 ➔ Apr 2027

Adverse events • Trial completion date • Trial primary completion date • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Efficacy of Aripiprazole on Cognitive Functions in Parkinson’s Disease: A Systematic Review and Meta-analysis (MDS Congress 2026) - No abstract available

Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

A case of tic improvement following tipepidine administration in a boy with Tourette syndrome comorbid with attention-deficit/hyperactivity disorder and autism spectrum disorder. (PubMed, PCN Rep) - "The addition of tipepidine was well tolerated, and the improvement in tic symptoms was maintained during long-term follow-up. This case suggests that adjunctive tipepidine may be well tolerated and associated with sustained improvement in motor and vocal tics during long-term follow-up in a patient with TS receiving aripiprazole."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Cough • Depression • Genetic Disorders • Movement Disorders • Psychiatry • Respiratory Diseases • Tourette Syndrome

Low-Dose Clozapine Versus Aripiprazole in Borderline Personality Disorder: A Prospective Naturalistic Study. (PubMed, J Clin Psychopharmacol) - "Our results suggest that low-dose clozapine is safe and may offer superior benefits for dissociative and depressive symptoms in patients with severe BLPD. Although further research is needed, these findings highlight the role of clozapine as a valuable pharmacological option in BLPD, particularly for patients with high clinical severity and inadequate response to other antipsychotics."

Journal • Borderline Personality Disorder • CNS Disorders • Depression • Mood Disorders • Personality Disorder • Psychiatry

Retrograde Ejaculation Associated With Paliperidone Palmitate: A Case Report. (PubMed, Clin Neuropharmacol) - "Paliperidone palmitate can induce retrograde ejaculation despite its lower alpha-1 adrenergic affinity compared with risperidone. This adverse effect may be underrecognized in clinical practice and can contribute to treatment nonadherence. Proactive assessment and appropriate treatment modification are essential to improve clinical outcomes."

Journal • CNS Disorders • Sexual Disorders • ADRA1B

A TiO2@MWCNTs-based dispersive solid-phase extraction method for mitigating matrix effects in plasma LC-MS/MS analysis. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "The matrix effects of representative small-molecule drugs, including metformin, amisulpride, and aripiprazole, were compared across TiO2@MWCNTs-based d-SPE, protein precipitation, and traditional solid-phase extraction. The validated method was also successfully applied to a pharmacokinetic study of metformin with pharmacokinetic parameters comparable to those reported previously. This study shows that the dispersive solid-phase extraction method based on TiO2@MWCNTs could act as a simple, rapid, low-cost and reliable pretreatment strategy to mitigate matrix effects for small-molecule analytes with low lgP in rat plasma as a proof-of-concept attempt."

Journal

Metformin, but Not Aripiprazole, Was Associated With Attenuation of Weight Gain in Clozapine-Treated Inpatients With Concurrent Disorders: A Repeated Measures Cohort Analysis: La metformine, mais non l'aripiprazole, a été associée à une atténuation du gain de poids chez les patients hospitalisés traités par la clozapine et présentant des troubles concomi (PubMed, Can J Psychiatry) - "Metformin was associated with attenuation of weight gain over time (time × metformin: B = -2.63, 95% CI -4.49 to -0.76), whereas aripiprazole was not (B = -0.38, 95% CI -2.58 to 1.82).ConclusionMetformin was associated with attenuation of weight gain trajectory in this population, whereas aripiprazole showed no clear effect. These findings highlight substantial metabolic vulnerability in inpatient concurrent disorders settings and support early preventive metabolic interventions during clozapine treatment."

Journal • CNS Disorders • Psychiatry • Schizophrenia

A Long-Term, Open-Label, Study on Schizophrenia (clinicaltrials.gov) - P2/3 | N=560 | Terminated | Sponsor: Denovo Biopharma LLC | N=1210 ➔ 560

Enrollment change • CNS Disorders • Psychiatry • Schizophrenia